Clinical trial
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With…
NCT00072709 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00072709 |
|---|---|
| Title | Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-Group, Multicenter, Dose-Ranging Study Evaluating Four Oral Doses of TCH346 (1.0, 2.5, 7.5 and 15 mg) Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Amyotrophic Lateral Sclerosis |
| Intervention type | Drug |
| Interventions | TCH346 |
| Enrollment | 551 |
| Start date | Sep 1, 2003 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Nov 11, 2003 |
| Last update posted | Nov 24, 2011 |
| Countries | Belgium, Canada, France, Germany, Italy, Netherlands, Switzerland, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: